Clinical Trial Update: Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma [Phase 2]

View source ↗

Summary

The Phase 2 clinical trial evaluating Sorafenib for advanced medullary thyroid carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Eanm Research Ltd | Conditions: Medullary Thyroid Carcinoma | Phase 2 | Status: WITHDRAWN